SLXN

In the past six months, Silexion Therapeutics Corp. has experienced several events impacting its stock price. On April 28, 2026, they announced the successful submission of a Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204. On March 24, 2026, they received approval from the Israeli Ministry of Health to initiate the Phase 2/3 clinical trial of SIL204. On March 17, 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results and provided a business update. On March 5, 2026, the company urged shareholders to vote ahead of a March 16 Extraordinary General Meeting. On January 6, 2026, Silexion Therapeutics Corp announced plans to initiate a Phase 2/3 clinical trial for SIL204. As of May 1, 2026, Silexion Therapeutics' stock price was $0.58, with a market capitalization of $2.44 million.